Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Receives Average Rating of “Moderate Buy” from Analysts

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) has been given an average rating of “Moderate Buy” by the six research firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $37.3333.

NBTX has been the subject of a number of analyst reports. HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a research report on Monday, May 18th. UBS Group raised their price target on Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research note on Friday, July 17th. Finally, Leerink Partners upped their price objective on Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a report on Thursday, June 4th.

Institutional Trading of Nanobiotix

Institutional investors and hedge funds have recently modified their holdings of the stock. Millennium Management LLC acquired a new stake in shares of Nanobiotix in the 4th quarter valued at approximately $390,000. Marshall Wace LLP bought a new position in Nanobiotix during the 4th quarter worth approximately $220,000. Finally, Royal Bank of Canada grew its holdings in Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after purchasing an additional 2,500 shares during the period. 38.81% of the stock is owned by institutional investors.

Nanobiotix Stock Performance

Shares of NASDAQ NBTX opened at $44.50 on Thursday. Nanobiotix has a fifty-two week low of $8.03 and a fifty-two week high of $57.14. The company’s 50 day simple moving average is $38.97 and its 200 day simple moving average is $35.90.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.